Uterine sarcoma is a – rare, aggressive, malignant and recurrent type of uterine cancer. In most cases, it is seen in elder women with an average age of 50-70 years. The diagnosis is difficult, symptoms vague and prognosis poorer than other types of gynaecological cancers.
Though it’s lethal, it is very rare. Uterine sarcoma represents only 1% of all gynaecological cancers and about 3–7% of all uterine malignancies. It is usually detected in postmenopausal women and the diagnosis is often accidental.
Explore more about uterine sarcoma symptoms, causes, prevention, screening, staging, treatment, statistics, survival rates and researches.
Uterine sarcoma is very rare. It represents only 1% of all gynaecological cancers, about 3–7% of all uterine malignancies and 4% of uterine cancers. The annual worldwide incidence of uterine sarcoma is 0.5 to 3.3 cases per 100,000 women.
Most cases are reported in postmenopausal women in the age range of 50-70. In the U.S, about 1200 women are diagnosed with uterine sarcoma each year. The estimated number of cases of uterine sarcoma in other countries are not available.
The presenting symptoms of uterine cancer are in most cases are vague and nonspecific. Usually, it causes abnormal vaginal bleeding, abdominal or pelvic pain, or a rapidly growing tumour. Uterine sarcoma is often challenging to detect as most of the symptoms for uterine sarcoma are same as other uterine malignancies.
Here are the common symptoms of uterine sarcoma –
The signs and symptoms might differ for each patient. But if the patient shows any of these symptoms or has a reason for suspicion then a visit to the gynaecologist is highly advised.
Uterine sarcoma is an aggressive kind of cancer. That means it grows rapidly and gets harder to treat with each passing day. So, in case of any suspicion early intervention is a must.
The aetiology of uterine sarcomas is still unclear. Researchers say that chromosomal translocations have an influence on a wide histological variety of sarcomas. But because of the rarity of this cancer type, the research and study on this particular type is scarce.
So far the known risk factors for uterine sarcoma are –
Radiation therapy in the pelvis area is a known risk factor for uterine sarcoma. Women may develop uterine sarcoma 5 to 25 years after radiation therapy.
Tamoxifen is a drug used in the treatment or prevention of breast cancer. It is targeted to reduce the effect of estrogen in breast tissues but amplify the estrogen impact in the uterus. Thus, increasing the risk of uterine cancer of all types. However, the benefits of this drug outweigh the risks.
About 5 per cent of all uterine cancer cases are linked to hereditary factors. The abnormal gene responsible for retinoblastoma increases the risk for uterine sarcoma. So, someone who had survived retinoblastoma should be more cautious.
The risk of uterine sarcoma is higher in women who had never been pregnant throughout their life. This is because during pregnancy, the production of progesterone is more and estrogen less.
Other risk factors like obesity, existing history of cancer, and familial history of cancer may also increase the risk of uterine sarcoma. However, these factors are no ultimatum for the occurrence of uterine cancer. There are a lot of other factors like the person’s general health and lifestyle choice that plays a role in most cases.
Because of the rarity of this cancer type, no large-scale studies or researches could be conducted. Hence, the aetiology and prevention of uterine cancer are not clear yet. However, knowing the risk factors and taking proper precautions can be helpful.
People who undergo radiation therapy or take tamoxifen for breast cancer treatment, should consult their healthcare provider to access the risk. In most cases, the benefits of these treatment methods outweigh the risks of developing a rare cancer like uterine sarcoma.
Other preventive approaches include –
The most preferred choice of treatment for uterine sarcoma is surgery. In most cases, surgery is done to remove the uterus, sometimes along with the fallopian tubes and ovaries. This is often followed by radiation, chemotherapy, hormone therapy or targeted therapy. Targeted therapy is opted for advancer cancers.
The doctor may choose one or more of the therapies for treating uterine sarcoma. For patients with critical health condition, where surgery is not a viable option, doctors opt for a combination of chemotherapy or hormone therapy.
After the cancer has been completely removed with surgery, the doctor may recommend adjuvant treatment. It is to help keep the cancer from coming back. Since, uterine sarcoma has a high recurrent rate with over 70% of patients reporting of cancer recurrence within one year, hence, adjuvant treatment is imperative.
Here is a detailed outline of the treatment procedures.
Possible risks or side effects of surgery
Surgery is an invasive kind of treatment. And there is certain risk and side effects associated with each type of surgery. But the risks or side effects often outweighs the benefits and that’s why it’s the most preferred option for treating uterine sarcoma.
Risks
Side Effects
Radiation therapy is a treatment for cancer which uses high energy X-rays to kill or shrink cancer cells while minimizing the damage to healthy cells. Radiation therapy can either be internal or external.
Uterine sarcoma is a rare-tumour with high malignant potential and poor prognosis. Because of its high recurrent nature, there is no curative treatment as of now. Also, the rarity of this disease adds to the difficulty of research and studies.
In case of uterine sarcoma, the only prognostic factor related to survival is the stage of the disease at diagnosis. Adjuvant therapies also do not offer much benefit in uterine sarcomas, it also does not alter the survival rates.
However, like any other cancer, for uterine sarcoma too open conversations about the symptoms, side-effects, mental health, emotional conditions, coping and recovering helps in better prognosis.
Uterine sarcoma has very high recurrence probability. Women who have been successfully treated for uterine sarcoma have a greater risk for certain other types of cancer, including breast cancer, colon cancer, bladder cancer, vaginal cancer, and rectal cancer.
Hence, women who have undergone treatment for uterine sarcoma should continue to follow-up for regular check-up. Also, postmenopausal women should visit a gynaecologist for an annual check-up. Young women who have familial history of cancer should also be more vigilant about abnormal bleeding, discharge or other changes in the body. Uterine sarcoma is very rare but lethal. Hence, being aware and alert about this cancer is very important for women of all ages.
Uterine Sarcoma is very aggressive in nature, that means it progresses at a rapid pace. So, if you spot any abnormal bleeding, discharge, pain or mass in the abdomen, act fast. Visit a gynaecologist, discuss your symptoms and ask the right questions.